Marta Missiaggia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Marta Missiaggia has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Francesco Cordoni
Department of Physics University of Trento Trento Italy
11 shared publications - Chiara La Tessa
University of Miami, Department of Radiation Oncology, 1475 Northwest 12th Avenue, Miami, FL 33136, United States
9 shared publications - Emanuele Scifoni
Trento Institute for Fundamental Physics and Applications (TIFPA), National Institute for Nuclear Physics (INFN), Trento, Italy
6 shared publications - Giorgio Cartechini
Maastricht University Medical Centre+, Department of Radiation Oncology (Maastro), GROW School for Oncology and Reproduction, Doctor Tanslaan 12, Maastricht 6229 ET, The Netherlands
3 shared publications - Giulio Bordieri
Department of Physics University of Trento Trento Italy
3 shared publications E. Scifoni
2 shared publications
Latest Publications
- 13 September 2026
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 126 (5) , 1529-1539
A Combined Dose and Microdosimetric Modeling Framework Incorporating Volume Effects Correlates with Tissue Sparing in Proton Minibeam Radiation Therapy
- 13 September 2026
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 126 (5) , 1529-1539
A Combined Dose and Microdosimetric Modeling Framework Incorporating Volume Effects Correlates with Tissue Sparing in Proton Minibeam Radiation Therapy
- 24 November 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (23) , 235016
Microdosimetry investigation of target fragments in proton therapy, assessing the impact of the detector type
Objective. Proton therapy is increasingly used in oncology due to its enhanced biological effectiveness and precision in targeting tumour tissues. Accurately characterising the radiation quality is, therefore, fundamental. However, the role of fragments in proton therapy remains understudied, mainly due to their low frequency of occurrence and limited impact on the dose. The fragments generated, though, interact differently with biological tissues and may substantially affect the biological response. This work characterises the fragments field generated by a typical clinical proton beam using microdosimetry. Approach. Experiments and Monte Carlo simulations were carried out for this purpose, using a 70.2 MeV proton beam moderated by a lung-equivalent material. Main results. Fragments contributed around 2% to y ¯ F and over 60% to y ¯ D , underscoring their relevance. The detector structure critically influenced their measurement, highlighting the necessity of detector-specific interpretation of spectra when used for biological modelling. Significance. Our results stress the importance of fragment-aware approaches for accurately assessing radiation quality and predicting biological outcomes in proton therapy.
- 24 November 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (23) , 235016
Microdosimetry investigation of target fragments in proton therapy, assessing the impact of the detector type
Objective. Proton therapy is increasingly used in oncology due to its enhanced biological effectiveness and precision in targeting tumour tissues. Accurately characterising the radiation quality is, therefore, fundamental. However, the role of fragments in proton therapy remains understudied, mainly due to their low frequency of occurrence and limited impact on the dose. The fragments generated, though, interact differently with biological tissues and may substantially affect the biological response. This work characterises the fragments field generated by a typical clinical proton beam using microdosimetry. Approach. Experiments and Monte Carlo simulations were carried out for this purpose, using a 70.2 MeV proton beam moderated by a lung-equivalent material. Main results. Fragments contributed around 2% to y ¯ F and over 60% to y ¯ D , underscoring their relevance. The detector structure critically influenced their measurement, highlighting the necessity of detector-specific interpretation of spectra when used for biological modelling. Significance. Our results stress the importance of fragment-aware approaches for accurately assessing radiation quality and predicting biological outcomes in proton therapy.
- Open Access
- 20 November 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 199, 111330
Integrating nano- and micrometer-scale energy deposition models for mechanistic prediction of radiation-induced DNA damage and cell survival
- 20 November 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 199, 111330
Open AccessIntegrating nano- and micrometer-scale energy deposition models for mechanistic prediction of radiation-induced DNA damage and cell survival
- Open Access
A novel methodology to estimate pileup effects and induced error in microdosimetric spectra
Microdosimetry provides a superior characterization of the radiation field compared to conventional LET-based methodology, and for this reason it has become increasingly attractive for quality assurance in particle therapy. However, the typical particle rates used in the treatments lead to pileup, which distorts the experimental spectra, and thus compromises the accuracy of microdosimetric measurements, limiting their use in clinical settings. In this work, we investigated the pileup in a spherical Tissue Equivalent Proportional Counter (TEPC), and developed an algorithm to evaluate the contribution of this effect to the measured spectra. We exposed the TEPC to 11 and 70 MeV proton beams, and collected the microdosimetric spectra at rates in the $10^3$-$10^6$ pps range. Using a combination of GEANT4 Monte Carlo simulations and experimental data, we develop an algorithm capable of estimating the pileup probability affecting experimental measurements. The data suggest that the pileup probability has a linear increase with rate until it reaches a value of $15 \pm 3 \, \%$ at $28.2 \times 10^3$ pps, at which point it begins to saturate. Additionally, the outcomes from the comparison of the two proton energies suggest that the methodology used to estimate pileup can be used to predict the effects in clinical proton beams with similar energies. This same methodology can be applied to any type of microdosimetric measurement making it a reliable tool for addressing pileup issues and facilitating the application of microdosimetry in clinical settings.Open AccessA novel methodology to estimate pileup effects and induced error in microdosimetric spectra
Microdosimetry provides a superior characterization of the radiation field compared to conventional LET-based methodology, and for this reason it has become increasingly attractive for quality assurance in particle therapy. However, the typical particle rates used in the treatments lead to pileup, which distorts the experimental spectra, and thus compromises the accuracy of microdosimetric measurements, limiting their use in clinical settings. In this work, we investigated the pileup in a spherical Tissue Equivalent Proportional Counter (TEPC), and developed an algorithm to evaluate the contribution of this effect to the measured spectra. We exposed the TEPC to 11 and 70 MeV proton beams, and collected the microdosimetric spectra at rates in the $10^3$-$10^6$ pps range. Using a combination of GEANT4 Monte Carlo simulations and experimental data, we develop an algorithm capable of estimating the pileup probability affecting experimental measurements. The data suggest that the pileup probability has a linear increase with rate until it reaches a value of $15 \pm 3 \, \%$ at $28.2 \times 10^3$ pps, at which point it begins to saturate. Additionally, the outcomes from the comparison of the two proton energies suggest that the methodology used to estimate pileup can be used to predict the effects in clinical proton beams with similar energies. This same methodology can be applied to any type of microdosimetric measurement making it a reliable tool for addressing pileup issues and facilitating the application of microdosimetry in clinical settings. - Open Access
- 24 December 2024
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (1) , 015005
Validation of the generalized stochastic microdosimetric model (GSM 2 ) over a broad range of LET and particle beam type: a unique model for accurate description of (therapy relevant) radiation qualities
Objective. The present work shows the first extensive validation of the generalized stochastic microdosimetric model (GSM2). This mechanistic and probabilistic model is trained and tested over cell survival experiments conducted with two cell lines (H460 and H1437), three different types of radiation (protons, helium, and carbon ions), spanning a very broad LET range from 1 keV μ m − 1 up to more than 300 keV μ m − 1 . Currently, the existing mechanistic radiation biophysical models show some limitations in describing cell killing without the addition of ad hoc corrections, especially in the high-LET regime, where the overkill effect is observed. Approach. The experimental irradiation conditions have been accurately reproduced with Monte Carlo simulations using the GEANT4-based TOPAS computational toolkit. We show the main and unique features of GSM 2 , i.e. how it can predict the biological response by considering the full information on the stochasticity of radiation through the microdosimetric spectrum, which is supposed to be the best descriptor of radiation quality. Main results. Well-matching results for different biological endpoints with the natural presence of the overkill effect fully display the predictive power of GSM2. Significance. This study shows the complete generality and flexibility of GSM2 and its ability to successfully predict the cell survival probability from very different particle radiation fields. Consequently, we demonstrate the dependence of the relative biological effectiveness on the whole microdosimetric spectrum, which fully includes the stochasticity inherently given by radiation-matter interaction.
- 24 December 2024
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (1) , 015005
Open AccessValidation of the generalized stochastic microdosimetric model (GSM 2 ) over a broad range of LET and particle beam type: a unique model for accurate description of (therapy relevant) radiation qualities
Objective. The present work shows the first extensive validation of the generalized stochastic microdosimetric model (GSM2). This mechanistic and probabilistic model is trained and tested over cell survival experiments conducted with two cell lines (H460 and H1437), three different types of radiation (protons, helium, and carbon ions), spanning a very broad LET range from 1 keV μ m − 1 up to more than 300 keV μ m − 1 . Currently, the existing mechanistic radiation biophysical models show some limitations in describing cell killing without the addition of ad hoc corrections, especially in the high-LET regime, where the overkill effect is observed. Approach. The experimental irradiation conditions have been accurately reproduced with Monte Carlo simulations using the GEANT4-based TOPAS computational toolkit. We show the main and unique features of GSM 2 , i.e. how it can predict the biological response by considering the full information on the stochasticity of radiation through the microdosimetric spectrum, which is supposed to be the best descriptor of radiation quality. Main results. Well-matching results for different biological endpoints with the natural presence of the overkill effect fully display the predictive power of GSM2. Significance. This study shows the complete generality and flexibility of GSM2 and its ability to successfully predict the cell survival probability from very different particle radiation fields. Consequently, we demonstrate the dependence of the relative biological effectiveness on the whole microdosimetric spectrum, which fully includes the stochasticity inherently given by radiation-matter interaction.
- Open Access
A multiscale radiation biophysical stochastic model describing the cell survival response at ultra-high dose rate
Ultra-high dose-rate (UHDR) radiotherapy, characterized by an extremely high radiation delivery rate, represents one of the most recent and promising frontier in radiotherapy. UHDR radiotherapy, addressed in the field as FLASH radiotherapy, is a disruptive treatment modality with several benefits, including significantly shorter treatment times, unchanged effectiveness in treating tumors, and clear reductions in side effects on normal tissues. While the benefits of UHDR irradiation have been well highlighted experimentally, the biological mechanism underlying the FLASH effect is still unclear and highly debated. Nonetheless, to effectively use UHDR radiotherapy in clinics, understanding the driving biological mechanism is paramount. Since the concurrent involvement of multiple scales of radiation damage has been suggested, we developed the MultiScale Generalized Stochastic Microdosimetric Model (MS-GSM2), a multi-stage extension of the GSM2, which is a probabilistic model describing the time evolution of the DNA damage in an irradiated cell nucleus. The MS-GSM2 can investigate several chemical species combined effects, DNA damage formation, and time evolution. We demonstrate that the MS-GSM2 can predict various in-vitro UHDR experimental results across various oxygenation levels, radiation types, and energies. The MS-GSM2 can accurately describe the empirical trend of dose and dose rate-dependent cell sensitivity over a wide range, consistently describing multiple aspects of the FLASH effect and reproducing the main evidence from the in-vitro experimental data. Our model also proposes a consistent explanation for the differential outcomes observed in normal tissues and tumors, in-vivo and in-vitro.
Open AccessA multiscale radiation biophysical stochastic model describing the cell survival response at ultra-high dose rate
Ultra-high dose-rate (UHDR) radiotherapy, characterized by an extremely high radiation delivery rate, represents one of the most recent and promising frontier in radiotherapy. UHDR radiotherapy, addressed in the field as FLASH radiotherapy, is a disruptive treatment modality with several benefits, including significantly shorter treatment times, unchanged effectiveness in treating tumors, and clear reductions in side effects on normal tissues. While the benefits of UHDR irradiation have been well highlighted experimentally, the biological mechanism underlying the FLASH effect is still unclear and highly debated. Nonetheless, to effectively use UHDR radiotherapy in clinics, understanding the driving biological mechanism is paramount. Since the concurrent involvement of multiple scales of radiation damage has been suggested, we developed the MultiScale Generalized Stochastic Microdosimetric Model (MS-GSM2), a multi-stage extension of the GSM2, which is a probabilistic model describing the time evolution of the DNA damage in an irradiated cell nucleus. The MS-GSM2 can investigate several chemical species combined effects, DNA damage formation, and time evolution. We demonstrate that the MS-GSM2 can predict various in-vitro UHDR experimental results across various oxygenation levels, radiation types, and energies. The MS-GSM2 can accurately describe the empirical trend of dose and dose rate-dependent cell sensitivity over a wide range, consistently describing multiple aspects of the FLASH effect and reproducing the main evidence from the in-vitro experimental data. Our model also proposes a consistent explanation for the differential outcomes observed in normal tissues and tumors, in-vivo and in-vitro.
- Open Access
- 17 July 2024
- Published by Springer Nature in The European Physical Journal Plus
- Vol. 139 (7) , 1-13
On the radiation quality characterization in radiation therapy: from linear energy transfer to experimental microdosimetry
Radiation-induced biological damage is primarily characterized by the average dose absorbed by the tissue. Nevertheless, it is acknowledged that other parameters, collectively constituting ”radiation quality,” play a crucial role in this context. However, defining and characterizing the radiation quality in radiotherapy to assess the radiobiological damage remains an open challenge. The most commonly used approach to quantify the radiation quality, the Linear Energy Transfer (LET), reveals many flaws in its applications. Microdosimetry represents an alternative approach that has been developed in the last decades and is considered a more accurate description of the radiation quality. Both approaches are explored, each with its inherent limitations and promising potential.
- 17 July 2024
- Published by Springer Nature in The European Physical Journal Plus
- Vol. 139 (7) , 1-13
Open AccessOn the radiation quality characterization in radiation therapy: from linear energy transfer to experimental microdosimetry
Radiation-induced biological damage is primarily characterized by the average dose absorbed by the tissue. Nevertheless, it is acknowledged that other parameters, collectively constituting ”radiation quality,” play a crucial role in this context. However, defining and characterizing the radiation quality in radiotherapy to assess the radiobiological damage remains an open challenge. The most commonly used approach to quantify the radiation quality, the Linear Energy Transfer (LET), reveals many flaws in its applications. Microdosimetry represents an alternative approach that has been developed in the last decades and is considered a more accurate description of the radiation quality. Both approaches are explored, each with its inherent limitations and promising potential.
- Open Access
- 5 February 2024
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 69 (4) , 045005
Integrating microdosimetric in vitro RBE models for particle therapy into TOPAS MC using the MicrOdosimetry-based modeliNg for RBE ASsessment (MONAS) tool
Objective. In this paper, we present MONAS (MicrOdosimetry-based modelliNg for relative biological effectiveness (RBE) ASsessment) toolkit. MONAS is a TOPAS Monte Carlo extension, that combines simulations of microdosimetric distributions with radiobiological microdosimetry-based models for predicting cell survival curves and dose-dependent RBE. Approach. MONAS expands TOPAS microdosimetric extension, by including novel specific energy scorers to calculate the single- and multi-event specific energy microdosimetric distributions at different micrometer scales. These spectra are used as physical input to three different formulations of the microdosimetric kinetic m odel , and to the generalized stochastic microdosimetric model (GSM 2 ), to predict dose-dependent cell survival fraction and RBE. MONAS predictions are then validated against experimental microdosimetric spectra and in vitro survival fraction data. To show the MONAS features, we present two different applications of the code: (i) the depth-RBE curve calculation from a passively scattered proton SOBP and monoenergetic 12 C-ion beam by using experimentally validated spectra as physical input, and (ii) the calculation of the 3D RBE distribution on a real head and neck patient geometry treated with protons. Main results. MONAS can estimate dose-dependent RBE and cell survival curves from experimentally validated microdosimetric spectra with four clinically relevant radiobiological models. From the radiobiological characterization of a proton SOBP and 12 C fields, we observe the well-known trend of increasing RBE values at the distal edge of the radiation field. The 3D RBE map calculated confirmed the trend observed in the analysis of the SOBP, with the highest RBE values found in the distal edge of the target. Significance. MONAS extension offers a comprehensive microdosimetry-based framework for assessing the biological effects of particle radiation in both research and clinical environments, pushing closer the experimental physics-based description to the biological damage assessment, contributing to bridging the gap between a microdosimetric description of the radiation field and its application in proton therapy treatment with variable RBE.
- 5 February 2024
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 69 (4) , 045005
Open AccessIntegrating microdosimetric in vitro RBE models for particle therapy into TOPAS MC using the MicrOdosimetry-based modeliNg for RBE ASsessment (MONAS) tool
Objective. In this paper, we present MONAS (MicrOdosimetry-based modelliNg for relative biological effectiveness (RBE) ASsessment) toolkit. MONAS is a TOPAS Monte Carlo extension, that combines simulations of microdosimetric distributions with radiobiological microdosimetry-based models for predicting cell survival curves and dose-dependent RBE. Approach. MONAS expands TOPAS microdosimetric extension, by including novel specific energy scorers to calculate the single- and multi-event specific energy microdosimetric distributions at different micrometer scales. These spectra are used as physical input to three different formulations of the microdosimetric kinetic m odel , and to the generalized stochastic microdosimetric model (GSM 2 ), to predict dose-dependent cell survival fraction and RBE. MONAS predictions are then validated against experimental microdosimetric spectra and in vitro survival fraction data. To show the MONAS features, we present two different applications of the code: (i) the depth-RBE curve calculation from a passively scattered proton SOBP and monoenergetic 12 C-ion beam by using experimentally validated spectra as physical input, and (ii) the calculation of the 3D RBE distribution on a real head and neck patient geometry treated with protons. Main results. MONAS can estimate dose-dependent RBE and cell survival curves from experimentally validated microdosimetric spectra with four clinically relevant radiobiological models. From the radiobiological characterization of a proton SOBP and 12 C fields, we observe the well-known trend of increasing RBE values at the distal edge of the radiation field. The 3D RBE map calculated confirmed the trend observed in the analysis of the SOBP, with the highest RBE values found in the distal edge of the target. Significance. MONAS extension offers a comprehensive microdosimetry-based framework for assessing the biological effects of particle radiation in both research and clinical environments, pushing closer the experimental physics-based description to the biological damage assessment, contributing to bridging the gap between a microdosimetric description of the radiation field and its application in proton therapy treatment with variable RBE.